Technology | Contrast Media | December 12, 2017

Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance

Scientists evaluate MR-based technology for differentiating treatment effects

Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance

December 12, 2017 — Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology, developed at Sheba Medical Center in Tel-Hashomer, Israel, with technology provided by Brainlab. The software analyzes magnetic resonance (MR) images to differentiate regions of efficient contrast clearance from regions with contrast accumulation in most cranial tumor patients to provide additional insight into post-treatment tumor characteristics.

“In conventional black and white MR images, it is often difficult to tell regions of high vascular activity apart from areas with damaged vasculature,” commented Yael Mardor, professor and chief scientist at The Advanced Technology Center of Sheba Medical Center. “Elements Contrast Clearance Analysis depicts contrast clearance efficiency of blood vessels in color to help clinicians better interpret the MR images and therefore support ongoing treatment assessment.”

Tissues that are highly vascularized and viable, such as active tumor tissue, are able to efficiently clear contrast agent within an hour of contrast injection. Conversely, regions consisting of damaged blood vessels, for example areas of necrosis, are unable to clear contrast agent as quickly, resulting in contrast accumulation. Based on this phenomenon, the software works by acquiring two MRI scans — one at 5 minutes and another at least one hour after injection of a standard dose of contrast agent — and intelligently subtracting the first series from the second to clearly show the difference between contrast clearance and accumulation.

“Elements Contrast Clearance Analysis has become part of our neuro-oncology team’s standard clinical practice, as it is simple, robust and complements our existing workflows,” commented Liam Welsh, M.D., consultant clinical oncologist at The Royal Marsden NHS Foundation Trust. “We have found every one of the scans analyzed for contrast clearance to be of assistance in our clinical decision-making. In the 30 percent of cases in which a subsequent decision was made to move forward with neurosurgery, we have observed a strong correlation between predicted and histologically observed viable tumor.”

Elements Contrast Clearance Analysis can provide critical insight to a multitude of specialties including radiation oncology, neurosurgery, neuro-oncology and neuroradiology.

Watch the VIDEO "How Serious is MRI Gadolinium Retention in the Brain and Body?"

Read the article "Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software"

For more information: www.brainlab.com

Related Content

Rafael Rivero, M.D., Global Head of Medical Affairs at MSI, said: "The importance of MyoStrain cannot be understated because of the test's immense clinical value and ability to quantify intramyocardial dysfunction across 48 segments of the heart. In a six-heartbeat MRI scan, MyoStrain arms physicians with novel clinical information about a patient's heart health."
News | Cardiac Imaging | August 11, 2020
August 11, 2020 — Myocardial Solutions, Inc. and United Imaging, Inc.
SyntheticMR announced its imaging software SyMRI is compatible with additional scanners from Siemens Healthineers on the US market, including 1.5T scanners such as Magnetom Altea, Sola and Sola Fit, as well as 3T scanners such as MAGNETOM Skyra and Prisma.
News | Information Technology | August 11, 2020
August 11, 2020 — SyntheticMR announced its imaging softwar
A special issue of the Journal of Medical Imaging and Radiation Sciences features stories about the interpersonal skills beyond the technical aspects to care for and guide patients through medical imaging and radiation therapy procedures

Image courtesy of Canon

News | Patient Engagement | August 11, 2020
August 11, 2020 — "I went into the MRI
High resolution in-vivo MR-STAT using a matrix-free and parallelized reconstruction algorithm being developed by Philips and UMC.

In-vivo T1, T2 and proton density maps reconstructed with MR-STAT using eight (first column), four (second column), two (third column) and one (fourth column) of the acquired k-spaces in the reconstruction. The acquisition times were 13.6, 6.8, 3.4 and 1.7 seconds respectively on a 1.5T Philips Ingenia MRI system. Find more images and information in this article.[1] 

 

News | Magnetic Resonance Imaging (MRI) | August 10, 2020
August 10, 2020 — During the International Society for Magnetic...
Imaging volumes in hospitals and practices previously slowed by the coronavirus pandemic continue to hold steady, according to new QuickPoLL survey results that gauge how radiologists feel about current business and the impact of COVID-19.
Feature | Coronavirus (COVID-19) | August 03, 2020 | By Melinda Taschetta-Millane
Imaging volumes in hospitals and practices previously slowed by the coronavirus pandemic continue to hold steady, acc
Franco Fontana, CEO of the Esaote Group, and Xie Yufeng, Chairman of WDM.

Franco Fontana, CEO of the Esaote Group, and Xie Yufeng, Chairman of WDM.

News | Digital Radiography (DR) | July 31, 2020
July 31, 2020 — In the thick of the COVID-19 eme
It covers every major modality, including breast imaging/mammography, fixed and portable C-arms (cath, IR/angio, hybrid, OR), CT, MRI, nuclear medicine, radiographic fluoroscopy, ultrasound and X-ray
News | Radiology Imaging | July 29, 2020
July 29, 2020 — IMV Medical Information, part of Scien...